Salt Lake City, UT, USA, September 7, 2016 – ProLungdx™ today announced plans to present its ground-breaking innovation for lung cancer patients at the AZBIO’s 2016 White Hat Life Science Investors Conference in Phoenix, Arizona September 21 and 22, 2016.
For the first time in an investment opportunity conference, prospective investors will be able to get a glimpse of ProLungdx’s Electro Pulmonary Nodule Scan™ or EPN Scan, a device designed to bridge the gap in the current standard of care between the detection of indeterminate pulmonary nodules and the risk of malignancy. “It is distressing that patients wait months or even years to determine if their lung nodule is cancer. This waiting time drastically reduces the treatment window for therapy. The EPN Scan’s purpose is to make a difference in time by reducing or eliminating the wait,” says Steven Eror, ProLungdx’s CEO.
The selection of ProLungdx to present alongside the most innovative life science companies at White Hat 2016 is significant. It highlights the rapidly accelerating concern following the introduction and reimbursement of the low-dose CT chest screen for lung cancer, which has been shown to have a 96% false positive rate for cancer. Leading medical experts universally agree that advances in lung cancer management present the largest opportunity to reduce cancer mortality.
“The Rocky Mountain Southwest Region is home to a wide range of exciting life science companies and diagnostics is one of our strongest areas,” shared Joan Koerber-Walker, president and CEO of AZBio and part of the organizing committee for White Hat 2016. “Companies from across the region competed to be selected for one of the 32 presentation slots and were scored and reviewed by a panel of active life science investors to get the […]